JP2004529207A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529207A5
JP2004529207A5 JP2003504987A JP2003504987A JP2004529207A5 JP 2004529207 A5 JP2004529207 A5 JP 2004529207A5 JP 2003504987 A JP2003504987 A JP 2003504987A JP 2003504987 A JP2003504987 A JP 2003504987A JP 2004529207 A5 JP2004529207 A5 JP 2004529207A5
Authority
JP
Japan
Prior art keywords
lhrh antagonist
methyl
medicines
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003504987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/004677 external-priority patent/WO2002102401A1/en
Publication of JP2004529207A publication Critical patent/JP2004529207A/ja
Publication of JP2004529207A5 publication Critical patent/JP2004529207A5/ja
Withdrawn legal-status Critical Current

Links

JP2003504987A 2001-04-30 2002-04-27 Lhrhアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療 Withdrawn JP2004529207A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (2)

Publication Number Publication Date
JP2004529207A JP2004529207A (ja) 2004-09-24
JP2004529207A5 true JP2004529207A5 (enExample) 2005-12-22

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003504987A Withdrawn JP2004529207A (ja) 2001-04-30 2002-04-27 Lhrhアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322L (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
PT1300398E (pt) 2000-07-05 2006-07-31 Astellas Pharma Inc Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
MXPA06014131A (es) * 2004-06-04 2007-03-07 Astellas Pharma Inc Derivado de propano-1,3-diona o su sal.
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
SI1864976T1 (sl) * 2005-03-31 2012-12-31 Astellas Pharma Inc. Propan-1,3-dionski derivat ali njegova sol
WO2008046919A2 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
AU2008303928A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
AU2008306264A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
CA2254769A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
EP1185530A1 (en) 1999-05-14 2002-03-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
MXPA02003614A (es) 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
US20030134863A1 (en) 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
PT1300398E (pt) * 2000-07-05 2006-07-31 Astellas Pharma Inc Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta

Similar Documents

Publication Publication Date Title
JP2005515966A5 (enExample)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
HK19395A (en) Film-coated solid dosage form of anti-migraine drug
CN1083265C (zh) 改进的含有布洛芬和可待因的药物配方
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
HUP0402230A2 (hu) Többszörös bevonattal ellátott gyógyszer dózisforma
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
RU2003134949A (ru) Способ лечения деменции и нейродегенеративных заболеваний и применение в нем качестве лекарственного средства промежуточных доз антагонистов lhrh
JP2004537500A5 (enExample)
JP2006515299A5 (enExample)
CA2508611A1 (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
US6528082B2 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
JP2002540148A5 (enExample)
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
JP2003523385A5 (enExample)
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
JP2005502690A5 (enExample)
JP4983750B2 (ja) 経口投与用製剤
ATE295169T1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist